The estimated Net Worth of Bruce Daugherty is at least 15 千$ dollars as of 21 June 2016. Dr Daugherty owns over 100,000 units of Tonix Pharmaceuticals Corp stock worth over 15,000$ and over the last 12 years he sold TNXP stock worth over 0$.
Dr has made over 6 trades of the Tonix Pharmaceuticals Corp stock since 2013, according to the Form 4 filled with the SEC. Most recently he bought 100,000 units of TNXP stock worth 200,000$ on 21 June 2016.
The largest trade he's ever made was buying 100,000 units of Tonix Pharmaceuticals Corp stock on 21 June 2016 worth over 200,000$. On average, Dr trades about 14,321 units every 80 days since 2013. As of 21 June 2016 he still owns at least 100,000 units of Tonix Pharmaceuticals Corp stock.
You can see the complete history of Dr Daugherty stock trades at the bottom of the page.
Dr. Bruce L. Daugherty M.B.A., Ph.D. is the Exec. VP of Research at Tonix Pharmaceuticals Corp.
Dr D is 63, he's been the Exec. VP of Research of Tonix Pharmaceuticals Corp since . There are 4 older and 9 younger executives at Tonix Pharmaceuticals Corp. The oldest executive at Tonix Pharmaceuticals Holding Corp is Adeoye Olukotun, 75, who is the Independent Director.
Bruce's mailing address filed with the SEC is C/O TONIX PHARMACEUTICALS HOLDING CORP, 509 MADISON AVE., SUITE 306, NEW YORK, NY, 10022.
Over the last 12 years, insiders at Tonix Pharmaceuticals Corp have traded over 155,884$ worth of Tonix Pharmaceuticals Corp stock and bought 1,820,071 units worth 3,399,062$ . The most active insiders traders include Ernest Mario、Seth Lederman、Bruce Daugherty. On average, Tonix Pharmaceuticals Corp executives and independent directors trade stock every 32 days with the average trade being worth of 2,734$. The most recent stock trade was executed by Seth Lederman on 29 June 2022, trading 20,000 units of TNXP stock currently worth 34,200$.
tonix is developing innovative pharmaceutical products to address major public health challenges. in addition to tonmya for ptsd, tonix is developing tnx-601 (tianeptine oxalate), a clinical candidate at pre-ind (investigational new drug) application stage, designed as a daytime treatment for ptsd and tnx-801, a live synthetic version of horsepox virus, at the pre-ind application stage, to be developed as a potential smallpox-preventing vaccine. further information about tonix can be found at www.tonixpharma.com.
Tonix Pharmaceuticals Corp executives and other stock owners filed with the SEC include: